Interferon-Beta Induces the Development of Type 2 Dendritic Cells

Author： Huang Y-M. Hussien Y. Yarilin D. Xiao B-G. Liu Y-J. Link H.

ISSN： 1043-4666

Source： Cytokine, Vol.13, Iss.5, 2001-03, pp. : 264-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Suppression of interleukin 12 (IL-12) production by dendritic cells (DCs) has been hypothesized to be a principal mechanism underlying the biological action of interferon (IFN)-β used for treatment of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system with possible autoimmune origin. How IFN-β interacts with DCs to inhibit IL-12 production remains unclear. In this study, we found that DCs derived from human blood monocytes, upon culture in the presence of IFN-β with granulocyte-macrophage colony- stimulating factor (GM-CSF) and IL-4, differentiated into a population expressing CD14^-CD1a^-HLA-DR⁺. This population expressed CD123 (IL-3Rα). IFN-β dose-dependently increased IL-3Rα⁺DCs and decreased CD1a⁺DCs. After 7 days'culture with IFN-β at a concentration of 10 000 U/ml, more than 40% of DCs expressed IL-3Rα. IFN-β, together with GM-CSF and IL-4, also induced maturation of IL-3Rα-expressing cells, as reflected by upregulation of HLA-DR and of the costimulatory molecules CD40, CD80 and CD86. In contrast to control DCs, IFN-β-treated DCs produced predominantly IL-10 but only low levels of IL-12p40. Correspondingly, IFN-β-treated DCs strongly suppressed IFN-γproduction but enhanced IL-10 production by allogeneic blood mononuclear cells. Our data suggest that IFN-β in vitro can induce the development of DC2, which provide a permissive environment for Th₂differentiation. This finding represents a novel mechanism for action of IFN-β in MS.